|
Time to deterioration (TTD) in health-related quality of life (HRQoL) with carfilzomib plus dexamethasone (Kd56) versus bortezomib plus dexamethasone (Vd) in the ENDEAVOR trial. |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Takeda |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Juno Therapeutics; Sanofi; Takeda |
Research Funding - Amgen; Celgene; Janssen |
|
|
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Takeda |
Research Funding - Amgen; Takeda |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Genesis Pharmaceuticals; Janssen-Cilag; Novartis; Takeda |
Consulting or Advisory Role - Amgen; Celgene; Janssen-Cilag; Takeda |
Research Funding - Amgen (Inst); Janssen-Cilag (Inst) |
Travel, Accommodations, Expenses - Amgen; Genesis Pharmaceuticals; Janssen-Ortho |
|
|
Honoraria - Amgen; Celgene; Janssen; Takeda |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Takeda |
Research Funding - Celgene; Janssen |
Travel, Accommodations, Expenses - Takeda |
|
|
No Relationships to Disclose |
|
|
Research Funding - Abbvie (Inst); Celgene (Inst); Sanofi (Inst) |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Amgen; Gilead Sciences |
Travel, Accommodations, Expenses - Amgen |
Other Relationship - Amgen |